Track topics on Twitter Track topics that are important to you
Pfizer and Sangamo Therapeutics revealed updated results from the Phase 1/2 Alta study, which demonstrated that SB-525 was generally well-tolerated and showed a dose-dependent increase in Factor VIII
The post Pfizer, Sangamo’s gene therapy show promise in phase 1/2 hemophilia A study appeared first on Pharmaceutical Business review.NEXT ARTICLE
Pfizer is a global pharmaceutical company, the largest in world based on annual sales. In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...